200 related articles for article (PubMed ID: 18363814)
1. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice.
Ovlisen K; Kristensen AT; Valentino LA; Hakobyan N; Ingerslev J; Tranholm M
J Thromb Haemost; 2008 Jun; 6(6):969-75. PubMed ID: 18363814
[TBL] [Abstract][Full Text] [Related]
2. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice.
Holmberg HL; Lauritzen B; Tranholm M; Ezban M
J Thromb Haemost; 2009 Sep; 7(9):1517-22. PubMed ID: 19566792
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
[TBL] [Abstract][Full Text] [Related]
4. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
Magisetty J; Pendurthi UR; Esmon CT; Rao LVM
Blood; 2020 Jun; 135(25):2211-2223. PubMed ID: 32294155
[TBL] [Abstract][Full Text] [Related]
5. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
6. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa.
Negrier C; Hay CR
Semin Thromb Hemost; 2000; 26(4):407-12. PubMed ID: 11092216
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
Gray LD; Hussey MA; Larson BM; Machlus KR; Campbell RA; Koch G; Ezban M; Hedner U; Wolberg AS
Thromb Res; 2011 Dec; 128(6):570-6. PubMed ID: 21561645
[TBL] [Abstract][Full Text] [Related]
8. Prevention of haemarthrosis in a murine model of acute joint bleeding.
Valentino LA; Hakobyan N; Kazarian T; Sorensen BB; Tranholm M
Haemophilia; 2009 Jan; 15(1):314-9. PubMed ID: 19149856
[TBL] [Abstract][Full Text] [Related]
9. Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.
Stagaard R; Flick MJ; Bojko B; Goryński K; Goryńska PZ; Ley CD; Olsen LH; Knudsen T
J Thromb Haemost; 2018 Jul; 16(7):1369-1382. PubMed ID: 29758126
[TBL] [Abstract][Full Text] [Related]
10. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.
Lisman T; de Groot PG; Lambert T; Røjkjaer R; Persson E
J Thromb Haemost; 2003 Oct; 1(10):2175-8. PubMed ID: 14521601
[TBL] [Abstract][Full Text] [Related]
11. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?
Rivard GE; Lillicrap D; Poon MC; Demers C; Lépine M; St-Louis J; Warner M
Haemophilia; 2005 Jul; 11(4):335-9. PubMed ID: 16011584
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.
Baudo F; de Cataldo F; Gaidano G;
Haematologica; 2004 Jun; 89(6):759-61. PubMed ID: 15194550
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
14. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
15. The F8(-/-) rat as a model of hemophilic arthropathy.
Sørensen KR; Roepstorff K; Wiinberg B; Hansen AK; Tranholm M; Nielsen LN; Kjelgaard-Hansen M
J Thromb Haemost; 2016 Jun; 14(6):1216-25. PubMed ID: 27060449
[TBL] [Abstract][Full Text] [Related]
16. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
[TBL] [Abstract][Full Text] [Related]
17. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats.
Lauritzen B; Tranholm M; Ezban M
J Thromb Haemost; 2009 Apr; 7(4):651-7. PubMed ID: 19175492
[TBL] [Abstract][Full Text] [Related]
18. Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report.
Kubisz P; Plamenová I; Stasko J; Dobrotová M; Hollý P
Thromb Haemost; 2010 Apr; 103(4):868-70. PubMed ID: 20135075
[No Abstract] [Full Text] [Related]
19. rFVIIa and NN1731 reduce bleeding in hydroxyethyl starch hemodiluted rabbits.
Lauritzen B; Viuff D; Tranholm M; Ezban M
J Trauma; 2010 Nov; 69(5):1196-202. PubMed ID: 20032791
[TBL] [Abstract][Full Text] [Related]
20. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.
Brinkhous KM; Hedner U; Garris JB; Diness V; Read MS
Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1382-6. PubMed ID: 2784006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
